Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S CLARITIN versus CLARITIN REDITABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S CLARITIN versus CLARITIN REDITABS.
CHILDREN'S CLARITIN vs CLARITIN REDITABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting second-generation antihistamine that selectively antagonizes peripheral histamine H1 receptors, thereby inhibiting the effects of histamine released from mast cells and basophils, reducing allergic symptoms.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
10 mg orally once daily
10 mg orally once daily.
None Documented
None Documented
The terminal elimination half-life of loratadine is 8-14 hours (mean 11 hours) in healthy adults; for the active metabolite descarboethoxyloratadine, half-life is 17-24 hours (mean 20 hours). This supports once-daily dosing.
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Loratadine is primarily eliminated via hepatic metabolism, with approximately 80% of the dose excreted as metabolites in urine (40%) and feces (40%). Less than 1% is excreted unchanged in urine.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Category C
Category C
Antihistamine
Antihistamine